Ask Sawal

Discussion Forum
Notification Icon1
Write Answer Icon
Add Question Icon

What is nda in regulatory affairs?

6 Answer(s) Available
Answer # 1 #

The FDA was initially established to regulate food and drug safety and prevent the sale of adulterated or misbranded products. However, when the Federal Food, Drug, and Cosmetic Act was passed in 1938, it set up the modern framework for the regulation of drugs in the US, expanding the agency’s responsibilities.

Now the FDA had the authority to approve or reject new drug products based on their safety and efficacy and to establish requirements for pre-market review and approval of new drugs. This allowed the FDA to enforce standards for the manufacture and distribution of drugs.

The requirement for pre-market evidence of a drug’s safety marked the inception of the New Drug Application (NDA). The firsts applications were submitted in the early 1940s, including applications for drugs that treated bacterial infections, hormone therapies, and mental health conditions.

These early NDAs set the stage for drug development and the FDA’s review and approval process for new drugs. Over the years, the FDA has reviewed and approved thousands of NDAs for new drug products.

When a company wants to market a new drug in the US, it must submit a marketing application to the FDA for review and approval. There are multiple types of marketing applications, including:

An NDA is a submitted request for permission to market a new drug product, including new molecular entities (NMEs), small molecules, biologics, vaccines, new combinations, new indications, and more.

The NDA must be submitted in a standard format, which is organized using the common technical document (CDT) format, a technical standard for all agency submissions starting from the IND phase. This format provides a standardized way of organizing and submitting regulatory information, and it helps to ensure that the information is consistent and easily accessible.

It’s typical for sponsors to use the Electronic Common Technical Document (eCTD) format, as it is regarded as the fastest delivery method to move the NDA process along between the sponsor and FDA.

Over the years, the application process has evolved to include more stringent requirements and greater scrutiny of the data submitted by drug manufacturers due to advancements in scientific understanding of drugs and their effects as well as increased public attention to drug safety and efficacy.

An NDA application needs to tell the comprehensive story of the drug and include data the FDA can use to determine whether or not the drug is safe for humans to use as intended. Sponsors must include a wide range of required information, including:

This information is used together to demonstrate that the product is safe for its intended use and target population, that its benefits outweigh the known risks, and that it can be manufactured in a way that ensures a high-quality product, and can be safely marketed to and used by patients and consumers.

NDAs are essential to drug development because they serve as the primary mechanism for the FDA to evaluate the safety and efficacy of new drugs, providing the federal agency with the information it needs to make an informed decision about whether a new drug should be approved for marketing and what conditions should be attached to its use.

By requiring rigorous preclinical and clinical testing and a comprehensive evaluation of the data, NDAs help to identify potential safety concerns and ensure that drugs are only approved for marketing if they are safe and effective. This can ultimately lead to better patient outcomes and advances in public health.

The NDA process also requires ongoing monitoring of the drug’s safety and efficacy through periodic reports and updates, providing a mechanism for public health officials and healthcare providers to receive accurate information about the drug.

Planning, preparing, and completing an NDA is a complex and multi-disciplinary effort that involves many different job roles, from nonclinical scientists to chemists to data management teams, physicians, pharmacologists, and more:

Each of these positions often play a critical role in the NDA process, and their collective efforts are necessary to ensure that a new drug is safe and effective for human use. Submitting an NDA with all the necessary data and information requires a lot of collaboration between all the different individuals and departments to be successful. Assembling a team right away can help streamline the application process.

Beginning the planning process for an NDA should start as early in the drug development process as possible to ensure a successful outcome. Start as soon as you understand the drug’s mechanism of action, safety profile, and efficacy data from preclinical studies.

Doing so can help you stay ahead of regulatory requirements, avoiding potential roadblocks. It also provides you more time to gather your data and perform any additional studies that may be required to support the NDA submission, minimizing delays and ensuring you have enough time to format your application correctly.

Understanding the mechanism of action will help you determine the best approach for testing the drug in clinical trials, while the safety profile and efficacy data from preclinical studies will provide important information about the drug’s potential benefits and risks.

The process includes several stages, beginning with an initial review and decision by the FDA to file the NDA or not, which must be made within 60 days of the application’s submission. If the team decides the application is complete, they have 6 to 10 months to decide whether to approve the drug for the market.

Then, the FDA’s Center for Drug Evaluation and Research (CDER) conducts a scientific review of the NDA, evaluating the data and information provided to assess the safety and efficacy of the drug.

The FDA’s Office of Regulatory Affairs will also conduct a regulatory review to ensure the NDA meets all of the FDA’s regulatory requirements. If deemed necessary, an Advisory Committee meeting may be held to provide independent expert opinions on the drug’s safety and efficacy.

Based on the scientific and regulatory reviews’ results, the FDA decides on the NDA and, if approved, issues a marketing approval. The NDA review process is critical to the FDA’s goal of ensuring that only safe and effective drugs are approved for use.

After all of the necessary steps and meetings have taken place, a final decision can be made based on the review of the NDA. If the drug is approved, the FDA sets conditions for its use, such as labeling requirements, post-marketing studies, and other commitments from the sponsor.

This evaluation process can sometimes take several years, but it is designed to ensure that new drugs are safe and effective for the intended population before making them available to the public.

The pre-NDA phase is a period of drug development that involves a combination of research and development, testing, and evaluation. It is critical to the success of the NDA process.

During the pre-NDA phase, drug makers conduct research to identify new drug candidates and evaluate their potential as treatments for various medical conditions, and it typically involves laboratory and animal testing.

Once the research has been completed, the drug maker moves on to pre-clinical testing, conducting more comprehensive safety and efficacy studies in animal models.

The primary goal here is to determine whether the drug can be safe and effective in humans and identify any potential toxicities or other issues that may arise during the clinical testing phase. The results of pre-clinical testing are then used to support the submission of an IND application.

The post-NDA phase occurs after a new drug product has received FDA approval for marketing in the US and has been made available for prescription and use by patients.

It is an essential part of the drug development process, as it provides ongoing monitoring of the drug’s use and safety and can help identify any potential issues or concerns that arise. It can also include additional regulatory requirements.

Some key activities during the post-NDA phase include post-marketing surveillance, adverse event reporting, label updates, and risk management plans.

Post-marketing surveillance involves continuously monitoring the drug after it has been approved through post-marketing surveillance programs, such as spontaneous reporting systems and ongoing clinical trials. Adverse event reporting encourages healthcare providers and patients to report any adverse events associated with drug use to the FDA or the sponsor.

Label updates occur when new information about a drug’s safety or efficacy comes to light, and post-approval studies are sometimes conducted upon the FDA’s request to gather more information about the drug’s safety and effectiveness.

Risk management plans and strategies can be implemented to minimize the risk of harm to patients in the future.

By monitoring the drug’s performance and collecting additional data, the FDA and the sponsor can make informed decisions about its use and identify any necessary changes to its labeling or risk management strategies.

Here are several tips for successfully submitting an NDA:

Submitting a successful NDA requires careful planning, a commitment to quality, and the help of regulatory affairs experts and legal counsel. These tips can help ensure that your NDA is complete, accurate, and meets all of the FDA’s requirements, increasing the chances of a successful outcome.

Developing a drug to submit for an NDA generally involves several steps, all of which need to happen in subsequent order. These steps include discovery and development, preclinical research, clinical research, FDA review, and FDA post-market safety monitoring.

Discovery and development involves identifying a potential target for a drug, finding and optimizing compounds that have potential activity against the target.

Preclinical testing involves conducting laboratory and animal testing to determine the safety and efficacy of the drug. If preclinical studies go well, the company can submit an IND application to the FDA, providing information about the drug’s composition, manufacturing processes, testing results, and the plans for clinical trials.

If the IND application is approved, the company can then conduct clinical trials to evaluate the drug’s safety and efficacy in humans. Trials are categorized into three phases, each involving an increasing number of patients.

If all three phases are completed, and the clinical trials are a success, the company can submit an NDA for approval, including detailed and updated information about the drug, its composition, the clinical trial results, and proposed labeling.

The FDA reviews the NDA and evaluates the data submitted by the drug maker, and conducts inspections of the facilities to ensure the product is being produced following good manufacturing practices.

After a thorough review, the FDA can approve or deny the drug for marketing in the US. The agency may determine that additional information is needed or request additional testing or data.

This is a high-level way to look at the steps to getting a drug approved for marketing in the US, which can take several years and require significant time and resources. The NDA submission and approval process alone is quite time-consuming, but it aims to ensure that new drugs that reach the market are both safe and effective and that the public can access accurate and reliable information about the medicines they take.

Commercialization can begin after FDA drug approval. Once the product has been approved to sell and market, the sponsor can start producing and selling the drug to healthcare providers and patients. This process involves a variety of manufacturing activities, including:

This is a critical stage in the drug development process, as it represents the transition from an experimental product to a marketed product available to patients.

Successful commercialization depends on many factors, including the size of the target patient population, the drug’s pricing and reimbursement status, and the competition in the market.

A New Drug Application (NDA) is a request submitted to the FDA seeking permission to bring a new drug product to market. This includes new molecular entities (NMEs), small molecules, biologics, vaccines, new combinations, new indications, and other similar products.

The submission process is organized using the common technical document (CTD) format, which is a standardized format used for all submissions to regulatory agencies, starting from the IND phase. The electronic CTD (eCTD) is considered the quickest and most efficient method for exchanging information between the submitting party and the FDA during the NDA process.

The accuracy and quality of your preclinical and clinical research, and your overall NDA submission, will play critical roles in receiving approval for a new drug product, and will depend on various factors, including the experience and expertise of the research team, the design and conduct of the preclinical and clinical trials, and the quality of the regulatory documentation.

That said, having access to the latest and most advanced equipment can help improve the efficiency and accuracy of your testing. Sadly, acquiring scientific instrumentation can be challenging.

When using your capital expenditure (CapEx) budget to procure new equipment doesn’t make financial sense, lease with Excedr. Our leasing program is an excellent cost-effective alternative to purchasing, which is often especially important for small or emerging companies working with limited resources.

Satyanshu Masurekar
Answer # 2 #

The Food and Drug Administration's (FDA) New Drug Application (NDA) is the vehicle in the United States through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing. Some 30% or less of initial drug candidates proceed through the entire multi-year process of drug development, concluding with an approved NDA, if successful.

The goals of the NDA are to provide enough information to permit FDA reviewers to establish the complete history of the candidate drug. Among facts needed for the application are:

Exceptions to this process include voter driven initiatives for medical marijuana in certain states.

To legally test the drug on human subjects in the U.S., the maker must first obtain an Investigational New Drug (IND) designation from FDA. This application is based on nonclinical data, typically from a combination of in vivo and in vitro laboratory safety studies, that shows the drug is safe enough to test in humans. Often the "new" drugs that are submitted for approval include new molecular entities or old medications that have been chemically modified to elicit differential pharmacological effects or reduced side effects.

The legal requirement for approval is "substantial" evidence of effectiveness demonstrated through controlled clinical trials. This standard lies at the heart of the regulatory program for drugs. Data for the submission must come from rigorous clinical trials.

The trials are typically conducted in three phases:

The legal requirements for safety and effectiveness have been interpreted as requiring scientific evidence that the benefits of a drug outweigh the risks and that adequate instructions exist for use, since many drugs have adverse side effects.

Many approved medications for serious illnesses (e.g., cancer) have severe and even life-threatening side effects. Even relatively safe and well understood OTC drugs such as aspirin can be dangerous if used incorrectly.

The results of the testing program are codified in an FDA-approved public document that is called the product label, package insert or Full Prescribing Information. The prescribing information is widely available on the web, from the FDA, drug manufacturers, and frequently inserted into drug packages. The main purpose of a drug label is to provide healthcare providers with adequate information and directions for the safe use of the drug.

The documentation required in an NDA is supposed to tell "the drug’s whole story, including what happened during the clinical tests, what the ingredients of the drug are, the results of the animal studies, how the drug behaves in the body, and how it is manufactured, processed and packaged.” Currently, the FDA decision process lacks transparency, however, efforts are underway to standardize the benefit-risk assessment of new medicines. Once approval of an NDA is obtained, the new drug can be legally marketed starting that day in the U.S.

Of original NDAs submitted in 2009, 94 out of 131 (72%) were in eCTD format.

Once the application is submitted, the FDA has 60 days to conduct a preliminary review, which assesses whether the NDA is "sufficiently complete to permit a substantive review." If the FDA finds the NDA insufficiently complete (reasons can vary from a simple administrative mistake in the application to a requirement to re-conduct testing), then the FDA rejects the application by sending the applicant a Refuse to File letter, which explains where the application failed to meet requirements. Where the application cannot be granted for substantive reasons, the FDA issues a Complete Response Letter.

Assuming the FDA finds everything acceptable, they decide if the NDA needs a standard or accelerated review, and communicates acceptance of the application and their review choice in another communication, known as the 74-day letter. A Standard Review implies an FDA decision within about 10 months while a Priority Review should complete within 6 months.

Biologics, such as vaccines and many recombinant proteins used in medical treatments are generally approved by FDA via a Biologic License Application (BLA), rather than an NDA. The manufacture of biologics is considered to differ fundamentally from that of less complex chemicals, requiring a somewhat different approval process.

Generic drugs that have already been approved via an NDA submitted by another maker are approved via an Abbreviated New Drug Application (ANDA), which does not require all of the clinical trials normally required for a new drug in an NDA. Most biological drugs, including a majority of recombinant proteins are considered ineligible for an ANDA under current US law. However, a handful of biologic medicines, including biosynthetic insulin, growth hormone, glucagon, calcitonin, and hyaluronidase are grandfathered under governance of the Federal Food Drug and Cosmetics Act, because these products were already approved when legislation to regulate biotechnology medicines later passed as part of the Public Health Services Act.

Medications intended for use in animals are submitted to a different center within FDA, the Center for Veterinary Medicine (CVM) in a New Animal Drug Application (NADA). These are also specifically evaluated for their use in food animals and their possible effect on the food from animals treated with the drug.

Bob Ellroy
Answer # 3 #

First, what is an IND? An IND is short for “Investigational New Drug” and is an application sent to the FDA for an exemption to lawfully transport and distribute an investigational new drug (a drug that has not been approved for sale) across state lines to conduct clinical trials and to administer it to humans. In other words, an IND is required when a sponsor intends to initiate a clinical trial or clinical investigation in humans

An IND application contains information in these three areas:

1. Animal Pharmacology and Toxicological Studies

2. Manufacturing Information

3. Clinical Protocols and Investigator Information

When an IND is submitted, the sponsor must wait 30 calendar days before initiating the clinical trial, unless an early notification is sent out by the FDA permitting the investigation to start. During the 30 calendar days, the FDA may order the sponsor to delay the clinical investigation by placing it on a “Clinical Hold” if the FDA concludes that a deficiency exists in a clinical investigation.

The NDA, on the other hand, is short for “New Drug Application“. Unlike an IND that comes in during the drug development process and right before the initiation of a clinical trial, an NDA signals the end of it. An NDA acts as a basis for the FDA to control and regulate new drugs in the United States. Since 1938, every investigational new drug is required to obtain market authorization before it can be legally marketed for sale in the United States. The NDA application serves the purpose of obtaining this market authorization. If a drug developer has enough evidence from the preclinical and clinical studies that the drug is safe and effective for its intended use, the company can file an NDA application to market the drug.

The ultimate goal of an NDA is to provide enough information to permit the FDA reviewer to determine the following questions:

The documents in the NDA tell the drug’s whole story, including what happened during the development process, the ingredients of the drug are, the results of the animal studies represent, the results from clinical studies represent, how the drug behaves in the body, and how the drug is being manufactured, processed, and packaged. All of these documents are required to be organized into five modules in an eCTD (electronic Common Technical Document) format. Refer to our blog “What is a Dossier in Regulatory Affairs” to find out more about eCTD requirements.

In addition to the study and manufacturing information, the application must also contain proposed labelling, safety updates, drug abuse information, patent information, any data from studies that may have been conducted outside the United States, institutional review board compliance information, and directions for use.

Once the FDA receives the NDA application, the reviewing team first reviews it for completeness. Completed applications will be reviewed and a decision on whether to approve the drug will be made within 6 to 10 months. Uncompleted applications are subject to refusal.

Hayedeh Corone
Chief Executive Officer
Answer # 4 #

For decades, the regulation and control of new drugs in the United States has been based on the New Drug Application (NDA). Since 1938, every new drug has been the subject of an approved NDA before U.S. commercialization.  The NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S.  The data gathered during the animal studies and human clinical trials of an Investigational New Drug (IND) become part of the NDA.

The goals of the NDA are to provide enough information to permit FDA reviewer to reach the following key decisions:

The documentation required in an NDA is supposed to tell the drug's whole story, including what happened during the clinical tests, what the ingredients of the drug are, the results of the animal studies, how the drug behaves in the body, and how it is manufactured, processed and packaged.  The following resources provide summaries on NDA content, format, and classification, plus the NDA review process:

The following resources have been gathered to provide you with the legal requirements of a new drug application, assistance from CDER to help you meet those requirements, and internal NDA review principles, policies and procedures.

Guidance documents represent the Agency's current thinking on a particular subject. These documents are prepared for FDA review staff and applicants/sponsors to provide guidelines to the processing, content, and evaluation/approval of applications and also to the design, production, manufacturing, and testing of regulated products.   They also establish policies intended to achieve consistency in the Agency's regulatory approach and establish inspection and enforcement procedures.  Because guidances are not regulations or laws, they are not enforceable, either through administrative actions or through the courts.  An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulations, or both. For information on a specific guidance document, please contact the originating office.

For the complete list of CDER guidances, please see the Guidance Index.  For information on a specific guidance document, please contact the originating office.

Guidance documents to help prepare NDAs:.

The mission of  FDA is to enforce laws enacted by the U.S. Congress and regulations established by the Agency to protect the consumer's health, safety, and pocketbook.  The Federal Food, Drug, and Cosmetic Act is the basic food and drug law of the U.S. With numerous amendments, it is the most extensive law of its kind in the world.  The law is intended to assure consumers that foods are pure and wholesome, safe to eat, and produced under sanitary conditions; that drugs and devices are safe and effective for their intended uses; that cosmetics are safe and made from appropriate ingredients; and that all labeling and packaging is truthful, informative, and not deceptive.

The final regulations published in the Federal Register (daily published record of proposed rules, final rules, meeting notices, etc.) are collected in the CFR.  The CFR is divided into 50 titles which represent broad areas subject to Federal regulations.  The FDA's portion of the CFR interprets the Federal Food, Drug and Cosmetic Act and related statutes.  Section 21 of the CFR contains all regulations pertaining to food and drugs.  The regulations document all actions of all drug sponsors that are required under Federal law.

These documents are approved instructions for internal practices and procedures followed by CDER staff to help standardize the new drug review process and other activities. MaPPs define external activities as well. All MaPPs are available for the public to review to get a better understanding of office policies, definitions, staff responsibilities and procedures.

MaPPS of particular interest to NDA applicants

On November 21, 1997, The President signed the Food and Drug Administration Modernization Act of 1997.  This legislation includes authorization for FDA to continue to collect three types of user fees from applicants who submit certain new drug and biological product applications.  FDA was first authorized to collect user fees under the Prescription Drug User Fee Act (PDUFA) of 1992.

Advisory committees provide independent advice and recommendations to the FDA on scientific and technical matters related to the development and evaluation of products regulated by the Agency.  CDER requests advice from advisory committees on a variety of matters, including various aspects of clinical investigations and applications for marketing approval of drug products.  Committee members are scientific experts such as physician-researchers and statisticians, as well as representatives of the public, including patients.  Although the committees provide recommendations to the Agency, final decisions are made by FDA.

agsvgsc Chalamuri
Answer # 5 #

Investigational New Drug (IND)

Current Federal law requires that a drug be the subject of an approved marketing application before it is transported or distributed across state lines. Because a sponsor will probably want to ship the investigational drug to clinical investigators in many states, it must seek an exemption from that legal requirement. The IND is the means through which the sponsor technically obtains this exemption from the FDA.  more

New Drug Application (NDA)

When the sponsor of a new drug believes that enough evidence on the drug's safety and effectiveness has been obtained to meet FDA's requirements for marketing approval, the sponsor submits to FDA a new drug application (NDA). The application must contain data from specific technical viewpoints for review, including chemistry, pharmacology, medical, biopharmaceutics, and statistics. If the NDA is approved, the product may be marketed in the United States.  For internal tracking purposes, all NDA's are assigned an NDA number.  more

Abbreviated New Drug Application (ANDA)

An Abbreviated New Drug Application (ANDA) contains data that, when submitted to FDA's Center for Drug Evaluation and Research, Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product. Generic drug applications are called "abbreviated" because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness.  Instead, a generic applicant must scientifically demonstrate that its product is bioequivalent (i.e., performs in the same manner as the innovator drug). Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, low cost alternative to the American public.   more

Over-the-Counter Drugs (OTC)

Over-the-counter (OTC) drugs play an increasingly vital role in America's health care system. OTC drug products are those drugs that are available to consumers without a prescription. There are more than 80 therapeutic categories of OTC drugs, ranging from acne drug products to weight control drug products. As with prescription drugs, CDER oversees OTC drugs to ensure that they are properly labeled and that their benefits outweigh their risks. more

Biologic License Application (BLA)

Biological products are approved for marketing under the provisions of the Public Health Service (PHS) Act. The Act requires a firm who manufactures a biologic for sale in interstate commerce to hold a license for the product. A biologics license application is a submission that contains specific information on the manufacturing processes, chemistry, pharmacology, clinical pharmacology and the medical affects of the biologic product. If the information provided meets FDA requirements, the application is approved and a license is issued allowing the firm to market the product. more

Rajasree Dhawan
Answer # 6 #

New Drug Application (NDA)

Rimsha Ahmed